Trial reportEuropean journal of medical research2025
Effects of varying-dose dexmedetomidine-assisted anesthesia on postoperative delirium in elderly patients undergoing radical mastectomy for breast cancer: a randomized controlled trial.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dexmedetomidine Improves BBB and Neuronal Damage in Subarachnoid Hemorrhage by Repressing S100A4-Mediated Astrocytic Reactivity.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThis study investigated the effects of different dexmedetomidine (DEX) doses on the occurrence of postoperative delirium (POD), assessed the levels of serum stress and inflammatory factors, and nerve injury markers in elderly patients undergoing radical mastectomy for breast cancer.
methodsIn this parallel randomized controlled study, 120 elderly patients undergoing radical mastectomy for breast cancer received 0.2, 0.5, or 0.8 μg/kg of DEX or 0.9% normal saline as the control. Baseline (T
resultsThe serum levels of S100β and NSE, norepinephrine and cortisol, IL-1β, IL-6, and TNF-α after treatment with 0.8 μg/kg DEX were significantly reduced compared to the control group. The POD incidences following treatment with 0.5 and 0.8 μg/kg DEX groups were comparable but significantly lower compared to the control group.
conclusionsThe DEX effect in POD down-regulation is dose-dependent. DEX (0.8 μg/kg) effectively reduces POD incidence in elderly patients undergoing radical mastectomy for breast cancer by inhibiting the production of pro-inflammatory cytokines. Registry: Chinese Clinical Trial Registry, ChiCTR2500101907. Registration date: 6th, May, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.